著者

石原 優 戸田 光 砂金 信義 太田 隆文

出版者

公益社団法人 日本薬学会

雑誌

YAKUGAKU ZASSHI (ISSN:00316903)

巻号頁・発行日

vol.131, no.5, pp.679-684, 2011-05-01 (Released:2011-05-01)

参考文献数

21

被引用文献数

5 6

---

Furanocoumarins (FCs) such as bergamottin (BG) and 6′,7′-dihydroxybergamottin (DHBG) contained in grapefruits are known to be cytochrome P450 3A4 (CYP3A4) inhibitors. These are contained in larger quantity in peel than in pulp, and therefore, processed peel products possibly have strong CYP3A4 inhibitory activity. The CYP3A4 inhibitory potency of these processed peel products, however, remains to be elucidated. The FC content and CYP3A inhibitory activities of various processed fruit peel products were investigated. CYP3A inhibitory activities of crystallized grapefruit peel, grapefruit marmalade, lemon peel and bitter orange slice were close to that of 100% grapefruit juice, while the activities of yuzu slice, pomelo (buntan) marmalade and crystallized iyokan peel were very weak, 1/8-1/20 of 100% grapefruit juice. The maximum BG content was 5.6 μg/g in lemon peel. The maximum DHBG content was 7.2 μg/g in crystallized grapefruit peel, about 1/30 that of raw peel. Grapefruit marmalade and crystallized grapefruit peel contained similar amounts of FCs to 100% grapefruit juice, but FCs were not detected in pomelo (buntan) marmalade or crystallized iyokan peel. Good correlation (r=0.78) was observed between the FC contents of these peel products and those CYP3A inhibitory activities. Preparation of homemade grapefruit marmalade and crystallized peel revealed that considerably lower DHBG content in these products and lower CYP3A inhibitory activity than anticipated were attributable to outflow of DHBG to broth during boiling of the raw peel.

著者

小合 由起 砂金 信義 太田 隆文 宇留野 強

出版者

公益社団法人 日本薬学会

雑誌

YAKUGAKU ZASSHI (ISSN:00316903)

巻号頁・発行日

vol.125, no.12, pp.1009-1011, 2005-12-01 (Released:2005-12-01)

参考文献数

2

被引用文献数

6 7

---

This study aimed to examine the effects of banana juice on levodopa bioavailability in rats. When a levodopa preparation (EC-Doparl tablets) was orally administered with banana juice made by mixing with a fresh banana and water, there were significant decreases in Cmax (17.4±2.5 vs. 8.6±3.1 μg/ml; α=0.05) and AUC (1882.8±49.2 vs. 933.5±286.6 μg•min/ml; α=0.05) for levodopa. On the other hand, administration of the levodopa preparation with a commercial beverage containing 10% banana juice resulted in no significant change in Cmax or AUC. These results indicate that concomitant intake of levodopa preparations with banana juice, but not with a commercial banana beverage, may cause a drug-food interaction reducing levodopa bioavailability, and we should pay attention to such interactions during levodopa therapy for patients with Parkinson's disease.

著者

小合 由起 砂金 信義 太田 隆文 宇留野 強

出版者

公益社団法人日本薬学会

雑誌

藥學雜誌 (ISSN:00316903)

巻号頁・発行日

vol.125, no.12, pp.1009-1011, 2005-12-01

被引用文献数

7

---

This study aimed to examine the effects of banana juice on levodopa bioavailability in rats. When a levodopa preparation (EC-Doparl tablets) was orally administered with banana juice made by mixing with a fresh banana and water, there were significant decreases in C_<max>(17.4±2.5vs.8.6±3.1μg/ml;α=0.05) and AUC(1882.8±49.2vs.933.5±286.6μg・min/ml;α=0.05) for levodopa. On the other hand, administration of the levodopa preparation with a commercial beverage containing 10% banana juice resulted in no significant change in C_<max> or AUC. These results indicate that concomitant intake of levodopa preparations with banana juice, but not with a commercial banana beverage, may cause a drug-food interaction reducing levodopa bioavailability, and we should pay attention to such interactions during levodopa therapy for patients with Parkinson's disease.

著者

砂金 信義 小合 由起 太田 隆文 宇留野 強

出版者

日本医療薬学会

雑誌

日本医療薬学会年会講演要旨集

巻号頁・発行日

vol.16, 2006-09-01

著者

飯田 淳子 砂金 信義 田中 裕子 太田 隆文

出版者

一般社団法人 日本医療薬学会

雑誌

日本医療薬学会年会講演要旨集 17 (ISSN:24242470)

巻号頁・発行日

pp.367, 2007-09-01 (Released:2019-01-19)

著者

砂金 信義 桑原 聖

出版者

一般社団法人 日本内科学会

雑誌

日本内科学会雑誌 (ISSN:00215384)

巻号頁・発行日

vol.96, no.6, pp.1163-1167, 2007 (Released:2012-08-02)

参考文献数

5

---

医薬品の副作用に関する情報源には医薬品添付文書があり,当該医薬品にとって特に注意を要する「重大な副作用」と「その他の副作用」に区分されて記載されている.薬剤性肺疾患を誘発する医薬品は多岐にわたるが,誘発疾患としては肺炎,間質性肺炎が多い.間質性肺炎誘発の恐れがある薬物には,抗悪性腫瘍薬,βラクタム系抗生物質,ニューキノロン系抗菌薬,抗リウマチ薬,抗てんかん薬,抗結核薬などがある.また,OTC薬あるいは健康食品でも発症が報告されており,医薬品,健康食品を用いるにあたっては間質性肺炎発症に留意する必要がある.